12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers China Pharma Holding (AMEX:CPHI) shares rose 12.7% to $0.12 during Thursday’s after-market session. The market value of…
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity In Treatment Resistant Mantle Cell Lymphoma
Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings Early Phase 1/2
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Connect Biopharma Hldgs (NASDAQ:CNTB) shares increased by 51.1% to $1.36 during Monday’s after-market session. The market value…
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 86.6% to $0.56 during Monday’s pre-market session. The market value…
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering.
Green Giant shares dipped 37.1% to $0.1599 in pre-market trading.
Here are some other stocks moving in pre-market trading.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Onconova Therapeutics (NASDAQ:ONTX) shares moved upwards by 42.5% to $0.9 during Friday’s after-market session. The company’s market…
Onconova Therapeutics’ Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell
• CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.